Business Context and Reporting Period
Company: BioLineRx Ltd.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2014
Accounting Standards: International Financial Reporting Standards (IFRS)
Reporting Currency: New Israeli Shekels (NIS), with U.S. Dollar (USD) translations provided.
BioLineRx is a clinical-stage biopharmaceutical development company incorporated in Israel. The company focuses on identifying, in-licensing, and developing therapeutic candidates for unmet medical needs. As of the reporting date, the company had no commercial products approved for sale and generated no product revenue. Its strategy relies heavily on out-licensing therapeutic candidates to third parties for development and commercialization.
Key Financial Metrics
| Metric (in thousands) | 2014 (NIS) | 2014 (USD) | 2013 (NIS) |
|---|---|---|---|
| Revenues | 0 | 0 | 0 |
| Research & Development Expenses | (42,443) | (10,914) | (44,057) |
| Sales & Marketing Expenses | (5,685) | (1,462) | (4,101) |
| General & Administrative Expenses | (13,591) | (3,495) | (13,225) |
| Operating Loss | (61,719) | (15,871) | (61,383) |
| Net Loss | (39,620) | (10,188) | (61,438) |
| Cash & Cash Equivalents | 22,519 | 5,790 | 30,888 |
| Short-term Bank Deposits | 112,354 | 28,890 | 32,345 |
| Total Liquidity (Cash + Deposits) | 134,873 | 34,680 | 63,233 |
| Total Assets | 140,827 | 36,211 | 69,469 |
| Total Liabilities | 17,133 | 4,406 | 28,783 |
| Shareholders' Equity | 123,694 | 31,806 | 40,686 |
Note: USD amounts are translated at the period-end exchange rate of 1 USD = 3.889 NIS.
Material Changes vs. Prior Period
- Net Loss Reduction: The net loss decreased significantly from NIS 61.4 million in 2013 to NIS 39.6 million in 2014. This improvement was primarily driven by a substantial increase in non-operating income (NIS 11.0 million in 2014 vs. NIS 4.2 million in 2013) due to fair-value adjustments on warrant liabilities, and a shift from net financial expenses to net financial income (NIS 12.8 million income in 2014 vs. NIS 4.3 million expense in 2013) resulting from currency fluctuations.
- Operating Expenses: Research and development (R&D) expenses decreased slightly by 3.7% to NIS 42.4 million, attributed to the termination of the BL-1020 clinical trial in 2013. Conversely, Sales and Marketing expenses increased by 38.6% to NIS 5.7 million, driven by professional fees related to new business development activities, including collaborations with Novartis and Omega Pharma.
- Liquidity Position: While total cash and short-term deposits decreased from NIS 63.2 million in 2013 to NIS 134.9 million in 2014 (an increase in NIS terms, but a decrease in USD terms due to currency translation and usage), the company raised significant capital in March 2015 (post-period) via a public offering of $28.8 million.
Guidance, Outlook, and Risks
Outlook and Capital Resources
Management believes that existing cash resources, combined with the $28.8 million raised in March 2015 and potential future milestone payments from partners, will be sufficient to fund operations into 2018. The company expects to continue incurring operating losses as it advances its clinical pipeline. Future capital requirements depend on the progress of clinical trials, regulatory approvals, and the success of out-licensing arrangements.
Key Developments
- Novartis Collaboration: In December 2014, BioLineRx entered a strategic collaboration with Novartis for the co-development of selected Israeli-sourced drug candidates. Novartis made an initial equity investment of $10 million.
- Omega Pharma Agreement: In December 2014, the company out-licensed BL-5010 (for OTC skin lesion indications) to Omega Pharma for Europe, Australia, and selected countries.
- Clinical Milestones: Enrollment for the PRESERVATION 1 trial (BL-1040) was completed in December 2014, with results expected in mid-2015. Phase 2 trials for BL-8040 (AML) and BL-7010 (Celiac disease) are ongoing or planned for 2015.
Risk Factors
- Regulatory Approval: The company has no approved products. Failure to obtain regulatory approval for any therapeutic candidate would prevent commercialization.
- Capital Requirements: The company has a history of losses and an accumulated deficit of NIS 545.4 million. It may require additional financing, which may not be available on favorable terms.
- Dependence on Partners: Commercialization relies on out-licensing partners (e.g., Bellerophon, Omega Pharma). Failure of these partners to meet milestones or financial obligations would adversely impact the company.
- Intellectual Property: The company relies on in-licensed IP. Termination of these agreements or challenges to patent validity (including oppositions filed against BL-1040 patents in Europe) could harm the business.
- Geopolitical Risks: Operations are based in Israel, exposing the company to regional political and military instability.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $34.7 million cash balance (as of Dec 31, 2014) plus the $28.8 million raised in March 2015 to fund operations through 2018 given the burn rate.
- BL-1040 Trial Results: Monitor the mid-2015 release of top-line results from the PRESERVATION 1 trial, which is critical for the company's most advanced asset and potential milestone payments from Bellerophon.
- Partner Performance: Assess the financial health and development progress of key partners, specifically Bellerophon (BL-1040) and Omega Pharma (BL-5010).
- Patent Oppositions: Track the status of the European Patent Office oppositions filed against BL-1040 patents in 2014.
- Government Funding Obligations: Review contingent liabilities related to the Israeli Office of the Chief Scientist (OCS), including potential repayment obligations if manufacturing is moved outside Israel.